Entero Therapeutics, Inc. Quarterly Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest in USD from Q3 2015 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
Summary
Entero Therapeutics, Inc. quarterly/annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest history and growth rate from Q3 2015 to Q1 2024.
  • Entero Therapeutics, Inc. Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for the quarter ending March 31, 2024 was -$9.29M, a 128% decline year-over-year.
  • Entero Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2020 was -$32.7M, a 115% decline from 2019.
  • Entero Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2019 was -$15.2M.
  • Entero Therapeutics, Inc. annual Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest for 2017 was -$11.1M, a 24% increase from 2016.
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Trailing 12 Months (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, Quarterly (USD)
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 -$9.29M -$5.22M -128% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-14
Q1 2023 -$4.07M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-14
Q1 2021 -$35.1M -$7.69M -$2.42M -46.1% Jan 1, 2021 Mar 31, 2021 10-Q 2021-05-24
Q4 2020 -$32.7M -$17.4M -$16.1M -1258% Oct 1, 2020 Dec 31, 2020 10-K 2021-03-31
Q3 2020 -$16.6M -$5.31M -$1.12M -26.7% Jul 1, 2020 Sep 30, 2020 10-Q 2020-11-16
Q2 2020 -$15.4M -$4.7M +$347K +6.88% Apr 1, 2020 Jun 30, 2020 10-Q 2020-08-14
Q1 2020 -$15.8M -$5.26M -$601K -12.9% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-24
Q4 2019 -$15.2M -$1.28M Oct 1, 2019 Dec 31, 2019 10-K 2021-03-31
Q3 2019 -$4.19M -$1.62M -63% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-16
Q2 2019 -$5.04M -$1.73M -52.4% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-14
Q1 2019 -$4.66M -$1.03M -28.3% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-15
Q3 2018 -$12M -$2.57M +$563K +18% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-14
Q2 2018 -$12.6M -$3.31M -$637K -23.9% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-13
Q1 2018 -$11.9M -$3.63M -$824K -29.3% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-15
Q4 2017 -$11.1M -$2.48M +$3.15M +55.9% Oct 1, 2017 Dec 31, 2017 10-K 2018-03-16
Q3 2017 -$14.2M -$3.13M +$63.9K +2% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-09
Q2 2017 -$14.3M -$2.67M +$1.1M +29.1% Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-13
Q1 2017 -$15.4M -$2.81M -$818K -41.1% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-14
Q4 2016 -$14.6M -$5.63M Oct 1, 2016 Dec 31, 2016 10-K 2018-03-16
Q3 2016 -$3.2M -$1.32M -70.7% Jul 1, 2016 Sep 30, 2016 10-Q 2017-11-13
Q2 2016 -$3.77M Apr 1, 2016 Jun 30, 2016 10-Q 2017-08-14
Q1 2016 -$1.99M Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-15
Q3 2015 -$1.87M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-25
* An asterisk sign (*) next to the value indicates that the value is likely invalid.